BR112015031416A2 - métodos para a promoção do desenvolvimento e/ou da saúde neuronal compreendendo a administração de uma combinação de ácido docosa-hexaenoico e ácido alfa-lipoico - Google Patents

métodos para a promoção do desenvolvimento e/ou da saúde neuronal compreendendo a administração de uma combinação de ácido docosa-hexaenoico e ácido alfa-lipoico

Info

Publication number
BR112015031416A2
BR112015031416A2 BR112015031416A BR112015031416A BR112015031416A2 BR 112015031416 A2 BR112015031416 A2 BR 112015031416A2 BR 112015031416 A BR112015031416 A BR 112015031416A BR 112015031416 A BR112015031416 A BR 112015031416A BR 112015031416 A2 BR112015031416 A2 BR 112015031416A2
Authority
BR
Brazil
Prior art keywords
methods
acid
health
alpha lipoic
administering
Prior art date
Application number
BR112015031416A
Other languages
English (en)
Inventor
Hondmann Dirk
K Poels Eduard
Chenzhong Kuang
Xiao Yan
Jouni Zeina
Original Assignee
Mjn Us Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mjn Us Holdings Llc filed Critical Mjn Us Holdings Llc
Publication of BR112015031416A2 publication Critical patent/BR112015031416A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/20—Dietetic milk products not covered by groups A23C9/12 - A23C9/18
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Botany (AREA)
  • Pediatric Medicine (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

a presente descrição refere-se a métodos para a promoção da saúde e/ou do desenvolvimento neuronal em um indivíduo, por meio do fornecimento de composições nutricionais compreendendo ácido docosa-hexaenoico e o ácido alfa-lipoico. a composição nutricional pode incluir ainda lactoferrina, um prebiótico, um probiótico, e misturas dos mesmos. adicionalmente, a presente descrição fornece métodos para acelerar o desenvolvimento da atividade neuronal e/ou o reforço da sinalização por sinapse eletroquímica, fornecendo a(s) composição(ões) nutricional(is), aqui revelada(s), a um indivíduo alvo.
BR112015031416A 2013-07-16 2014-06-21 métodos para a promoção do desenvolvimento e/ou da saúde neuronal compreendendo a administração de uma combinação de ácido docosa-hexaenoico e ácido alfa-lipoico BR112015031416A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/942,827 US9226914B2 (en) 2013-07-16 2013-07-16 Methods for promoting neuronal development and/or health
PCT/US2014/043532 WO2015009407A1 (en) 2013-07-16 2014-06-21 Methods for promoting neuronal development and/or health comprising administration of a combination of docosahexaenoic acid and alpha-lipoic acid

Publications (1)

Publication Number Publication Date
BR112015031416A2 true BR112015031416A2 (pt) 2017-07-25

Family

ID=51210794

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015031416A BR112015031416A2 (pt) 2013-07-16 2014-06-21 métodos para a promoção do desenvolvimento e/ou da saúde neuronal compreendendo a administração de uma combinação de ácido docosa-hexaenoico e ácido alfa-lipoico

Country Status (13)

Country Link
US (1) US9226914B2 (pt)
EP (1) EP3102196A1 (pt)
CN (1) CN105358144B (pt)
AR (1) AR096942A1 (pt)
AU (1) AU2014290767A1 (pt)
BR (1) BR112015031416A2 (pt)
CA (1) CA2918460A1 (pt)
HK (1) HK1221658A1 (pt)
MX (1) MX2016000423A (pt)
PH (1) PH12016500025A1 (pt)
SG (1) SG11201510330YA (pt)
TW (1) TW201542101A (pt)
WO (1) WO2015009407A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150290261A1 (en) * 2014-04-10 2015-10-15 Mead Johnson Nutrition Company Methods of use for probiotics and prebiotics
US10525016B2 (en) * 2015-06-03 2020-01-07 Mead Johnson Nutrition Company Nutritional compositions containing an elevated level of inositol and uses thereof
US10617701B2 (en) * 2015-07-10 2020-04-14 Mead Johnson Nutrition Company Nutritional compositions containing phosphatidylethanolamine, sphingomyelin and docosahexaenoic acid
CN110891982B (zh) 2017-04-17 2023-12-22 芝加哥大学 向肠道递送短链脂肪酸以用于人体保健和疾病治疗的聚合物材料
US11197917B2 (en) 2017-12-01 2021-12-14 ByHeart, Inc. Formulations for nutritional support in subjects in need thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE61701B1 (en) 1986-07-17 1994-11-30 Morinaga Milk Industry Co Ltd Process for producing bovine lactoferrin in high purity
US5407957A (en) 1990-02-13 1995-04-18 Martek Corporation Production of docosahexaenoic acid by dinoflagellates
DK165090D0 (da) 1990-07-09 1990-07-09 Kem En Tec As Konglomererede partikler
WO1992012711A1 (en) 1991-01-24 1992-08-06 Martek Corporation Microbial oil mixtures and uses thereof
US5374567A (en) 1993-05-20 1994-12-20 The United States Of America As Represented By The Secretary Of The Navy Operational amplifier using bipolar junction transistors in silicon-on-sapphire
EP0744901B1 (en) 1994-02-16 2001-12-05 Pharming Intellectual Property BV Isolation of lactoferrin from milk
SE9503926D0 (sv) 1995-11-07 1995-11-07 Pharmacia Biotech Ab Adsorptionsförfarande och separationsmedium
GB9715444D0 (en) 1997-07-22 1997-09-24 Scotia Holdings Plc Therapeutic and dietary compositions
EP1087828B1 (en) 1998-06-18 2008-09-17 Upfront Chromatography A/S Expanded bed adsorption system
AU5823801A (en) 2000-05-12 2001-11-20 Upfront Chromatography As A bed adsorption system
US6332533B1 (en) 2000-08-29 2001-12-25 H.H.H. Incorprorated Media holder mouse pad
EP2272378B1 (en) 2001-06-01 2014-08-06 Upfront Chromatography A/S Fractionation of protein containing mixtures
AU2003218623B2 (en) 2002-03-07 2008-01-17 Upfront Chromatography A/S A process of isolating lactoferrin
US20050107338A1 (en) 2003-11-17 2005-05-19 Seidman Michael D. Nutritional supplement enhancing mitochondrial function
CN103734746B (zh) * 2004-07-19 2017-01-11 纽崔西亚公司 天冬氨酸用于调节血中葡萄糖水平的用途
US8883814B2 (en) 2006-06-05 2014-11-11 Keyview Labs, Inc. Compositions and methods for enhancing brain function
US20080003330A1 (en) 2006-06-30 2008-01-03 Ricardo Rueda Infant formulas for early brain development
EP2251030A1 (en) 2009-05-12 2010-11-17 Nestec S.A. Lactoferrin and brain health and development in infants
EP2258218A1 (en) 2009-06-02 2010-12-08 Nestec S.A. Nutritional Composition for Supporting Brain Development and Function of Toddlers
US20120219526A1 (en) 2009-10-29 2012-08-30 Nestec S.A. Nutritional compositions comprising lactoferrin and probiotics and kits of parts thereof
WO2011069987A1 (en) * 2009-12-08 2011-06-16 Nestec S.A. Infant formula with probiotics and milk fat globule membrane components
EP2554058A4 (en) * 2010-03-31 2013-12-25 Vegenat S A FUNCTIONAL FOOD SUPPLEMENT, IN PARTICULAR FOR NUTRITIONAL AND PREVENTION AND IMPROVEMENT OF NEUROLOGICAL ILLNESSES, NEURODEEGENERATIVE ILLNESSES OR COGNITIVE DISORDERS
US8968722B2 (en) * 2010-12-29 2015-03-03 Mead Johnson Nutrition Company Milk-based nutritional compositions containing lactoferrin and uses thereof
CN102318827B (zh) 2011-07-15 2013-02-27 浙江康恩贝健康产品有限公司 一种促进神经系统发育的营养素组合物及保健品
EP2609814A1 (en) 2011-12-30 2013-07-03 Nestec S.A. Lactobacillus reuteri DSM 17938 for the development of cognitive function
US20140179775A1 (en) 2012-02-29 2014-06-26 Mead Johnson Nutrition Company Neurogenesis screening method and uses thereof
US20140199265A1 (en) 2013-01-11 2014-07-17 Mead Johnson Nutrition Company Nutritional compositions containing a neurologic component and uses thereof

Also Published As

Publication number Publication date
US9226914B2 (en) 2016-01-05
CA2918460A1 (en) 2015-01-22
AU2014290767A1 (en) 2015-12-24
EP3102196A1 (en) 2016-12-14
PH12016500025A1 (en) 2016-03-28
AR096942A1 (es) 2016-02-10
WO2015009407A1 (en) 2015-01-22
SG11201510330YA (en) 2016-01-28
CN105358144B (zh) 2018-05-11
CN105358144A (zh) 2016-02-24
US20150023923A1 (en) 2015-01-22
MX2016000423A (es) 2016-04-20
HK1221658A1 (zh) 2017-06-09
TW201542101A (zh) 2015-11-16

Similar Documents

Publication Publication Date Title
BR112016024850A2 (pt) composições e métodos para modulação da expressão 3 semelhante a antiopoietina
BR112015015898A2 (pt) composição farmacêutica de solução sólida
BR112016027871A2 (pt) composição para melhorar a memória, a função de aprendizado e/ou função cognitiva
BR112015031416A2 (pt) métodos para a promoção do desenvolvimento e/ou da saúde neuronal compreendendo a administração de uma combinação de ácido docosa-hexaenoico e ácido alfa-lipoico
BR112015005894A2 (pt) composição farmacêutica
BR112017005693A2 (pt) método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica.
BR112015005048A2 (pt) métodos para tratar dermatite atópica por administração de antagonista il-4r
ECSP17043318A (es) Composición que contiene quitina y proteínas digeribles
BR112015015870A2 (pt) composição farmacêutica
BR112014016251A2 (pt) composições e métodos para modificação da flora gastrointestinal
BR112014006587A8 (pt) Composto compreendendo oligonucleotídeo que modula a expressão de gcgr, composição, bem como seu uso no tratamento ou prevenção de diabetes
BR112014031874A2 (pt) método para preparar células-tronco em concentração elevada
BR112015003729A8 (pt) Composto de fórmula estrutural i; composição farmacêutica; método de tratamento de uma doença mediada por caminho do hif; método de tratamento de uma doença causada por proliferação anormal de células; e método para alcançar um efeito em um paciente
BR112018003745A2 (pt) composições que compreendem um composto de urolitina
BR112015022514A2 (pt) composições que compreendem selênio e uso das mesmas para o tratamento e prevenção de doença ou condições associadas à disfunção mitocondrial
BR112018072064B8 (pt) Uso de triglicerídeos de cadeia média para preparação de composições nutricionais para proteção cardíaca em animais de estimação
BR112018076283A2 (pt) métodos e composições para potencializar terapias de célula tronco
BR112016010875A8 (pt) Composição útil para a promoção da fertilidade feminina
BR112015015864A2 (pt) composição farmacêutica, método de preparação de uma composição farmacêutica, método de tratamento de um indivíduo com uma condição de dor severa, e, uso de uma composição farmacêutica
BR112013017314A2 (pt) composições compreendendo inibidores de cotransportadores 1 e 2 de sódio-glicose e métodos de usos
BR112015005653A2 (pt) Método de promover o desenvolvimento de oócitos maduros e de aumentar a polimerização de actina em tecido ovariano, e uso de um agente que perturba a sinalização na trajetória hippo, ou um agente que age a jusante da sinalização hippo perturbada
BR112018003780A2 (pt) composições que compreendem um composto de urolitina
BR112018000242A2 (pt) composições nutricionais contendo fosfatidiletanolamina, esfingomielina e ácido doco-saexaenóico
BR112015018265A2 (pt) Composições nutricionais contendo um componente peptídico com propriedades estimulantes de adiponectina e utilizações das mesmas
BR112012019920A2 (pt) derivados de piridazina úteis como agonístas de canabinoide-2.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 31/202 (2006.01)

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]